Abstract
Purpose
To examine the factors associated with gynecologic cancer mortality risks, to estimate the mortality-to-incidence rate ratios (MIR) in Trinidad and Tobago (TT), and to compare the MIRs to those of select countries.
Methods
Data on 3,915 incident gynecologic cancers reported to the National Cancer Registry of TT from 1 January 1995 to 31 December 2009 were analyzed using proportional hazards models to determine factors associated with mortality. MIRs for cervical, endometrial, and ovarian cancers were calculated using cancer registry data (TT), GLOBOCAN 2012 incidence data, and WHO Mortality Database 2012 data (WHO regions and select countries).
Results
Among the 3,915 incident gynecologic cancers diagnosed in TT during the study period, 1,795 (45.8%) were cervical, 1,259 (32.2%) were endometrial, and 861 (22.0%) were ovarian cancers. Older age, African ancestry, geographic residence, tumor stage, and treatment non-receipt were associated with increased gynecologic cancer mortality in TT. Compared to GLOBOCAN 2012 data, TT MIR estimates for cervical (0.49 vs. 0.53), endometrial (0.61 vs. 0.65), and ovarian cancers (0.32 vs. 0.48) were elevated. While the Caribbean region had intermediate gynecologic cancer MIRs, MIRs in TT were among the highest of the countries examined in the Caribbean region.
Conclusions
Given its status as a high-income economy, the relatively high gynecologic cancer MIRs observed in TT are striking. These findings highlight the urgent need for improved cancer surveillance, screening, and treatment for these (and other) cancers in this Caribbean nation.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Journal International du Cancer (Int J Cancer) 136:E359–E386
Weiderpass E, Labreche F (2012) Malignant tumors of the female reproductive system. Saf Health Work 3:166–180
Razzaghi H, Quesnel-Crooks S, Sherman R et al (2016) Leading causes of cancer mortality—Caribbean region, 2003–2013. MMWR Morb Mortal Wkly Rep 65:1395–1400
Melan K, Janky E, Macni J et al (2017) Epidemiology and survival of cervical cancer in the French west-indies: data from the martinique cancer registry (2002–2011). Glob Health Action 10:1337341
Blake G, Hanchard B, Gibson T et al (2003) Gynaecologic cancer incidence, Kingston and St Andrew, Jamaica, 1973–1997, and gynaecologic cancer mortality, Jamaica, 1999. West Indian Med J 52:273–277
Gelband H, Sankaranarayanan R, Gauvreau CL et al. (2016) Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from disease control priorities, 3rd edn. Lancet 387:2133–2144
Pinheiro PS, Callahan KE, Ragin C, Hage RW, Hytlon T, Kobetz EN (2016) Black heterogeneity in cancer mortality: Us-blacks, Haitians, and Jamaicans. Cancer Control 23:347–358
Lewis-Bell K, Luciani S, Unger ER et al (2013) Genital human papillomaviruses among women of reproductive age in Jamaica. Revista Panamericana de Salud Publica (Pan Am J Publ Health) 33:159–165
Bahadoor-Yetman A, Riley L, Gibbons A et al (2016) Prevalence of cervical cancer and associated mortality in grenada, 2000–2010. Revista Panamericana de Salud Publica (Pan Am J Publ Health) 39:194–199
(PAHO) PAHO (2013) Cancer in the Americas, country profiles 2013. PAHO, Washington, D.C.
Ortiz AP, Perez J, Otero-Dominguez Y et al (2010) Endometrial cancer in puerto rico: incidence, mortality and survival (1992–2003). BMC Cancer 10:31
Warner WA, Morrison RL, Lee TY et al (2015) Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. Cancer Med 4(11):1742–1753
Boyle P, Parkin D (1991) Cancer registration: principles and methods. Statistical methods for registries. IARC Sci Publ 95:126–158
Jensen O, McLeannan R, Muir C, Skeet G (1991) Cancer registration: principles and methods. IARC Sci Publ 95
Fritz A, Percy C, Jack A et al (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva
Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–1957). Sendai Department of Public Health, Tohoku University of Medicine, Sendai
World Health Organization (2016) World health organization, health statistics and information systems, mortality database. Geneva
Ferlay J, Soerjomataram I, Ervik M et al (2013) Globocan 2012 v1.0, cancer incidence and mortality worldwide: Iarc cancerbase no. 11. International Agency for Research on Cancer, Lyon
Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD (2005) Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ 83:171–177
Bruni L, Barrionuevo-Rosas L, Albero G et al. (2016) Human papillomavirus and related diseases in Trinidad & Tobago. Summary report 15
Lewis MJ (2004) A situational analysis of cervical cancer in latin america and the caribbean. Pan American Health Organization, Washington DC
Andall-Brereton GM, Hosein F, Salas RA et al (2011) Human papillomavirus genotypes and their prevalence in a cohort of women in Trinidad. Revista Panamericana de Salud Publica (Pan Am J Publ Health) 29:220–226
Ragin CC, Wheeler VW, Wilson JB et al. (2007) Distinct distribution of hpv types among cancer-free afro-caribbean women from tobago. Biomarkers 12:510–522
Hosein F, Mohammed W, Zubach V, Legall G, Severini A (2013) Human papillomavirus genotypes in invasive cervical squamous cell carcinoma in Trinidad. Revista Panamericana de Salud Publica (Pan Am J Publ Health) 33:267–270
Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244–265
Islami F, Torre LA, Drope JM, Ward EM, Jemal A (2017) Global cancer in women: cancer control priorities. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Lu KH, Dinh M, Kohlmann W et al (2005) Gynecologic cancer as a sentinel cancer for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105:569–574
Obermair A, Youlden DR, Young JP et al (2010) Risk of endometrial cancer for women diagnosed with hnpcc-related colorectal carcinoma. Int J Cancer 127:2678–2684
Gayther SA, Pharoah PD (2010) The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 20:231–238
Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB (2011) Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 4:15–21
Kirchhoff T, Gaudet MM, Antoniou AC et al (2012) Breast cancer risk and 6q22.33: combined results from breast cancer association consortium and consortium of investigators on modifiers of brca1/2. PLoS ONE 7:e35706
Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a brca2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034
Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to chek2(*)1100delc in noncarriers of brca1 or brca2 mutations. Nat Genet 31:55–59
Michailidou K, Hall P, Gonzalez-Neira A et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45:353–361
Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of brca1 and brca2 among ashkenazi jews. New Engl J Med 336:1401–1408
Thorlacius S, Olafsdottir G, Tryggvadottir L et al (1996) A single brca2 mutation in male and female breast cancer families from iceland with varied cancer phenotypes. Nat Genet 13:117–119
Thorlacius S, Struewing JP, Hartge P et al (1998) Population-based study of risk of breast cancer in carriers of brca2 mutation. Lancet 352:1337–1339
NCCN (2016) Nccn guidelines version1.2016 NCCN
SGO (2014) Sgo clinical practice statement: genetic testing for ovarian cancer. SGO, Chicago
Pal T, Permuth-Wey J, Betts JA et al (2005) Brca1 and brca2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807–2816
Schrader KA, Hurlburt J, Kalloger SE et al (2012) Germline brca1 and brca2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol 120:235–240
Walsh T, Casadei S, Lee MK et al (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108:18032–18037
Kaye SB, Lubinski J, Matulonis U et al (2012) Phase ii, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (adp-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with brca1 or brca2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372–379
Donenberg T, Ahmed H, Royer R et al (2016) A survey of brca1, brca2, and palb2 mutations in women with breast cancer in Trinidad and Tobago. Breast Cancer Res Treat 159:131–138
Roach A, Warner WA, Llanos AA (2015) Building capacity for human genetics and genomics research in Trinidad and Tobago. Revista Panamericana de Salud Publica (Pan Am J Publ Health) 38:425–430
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA: A Cancer J Clin 65:87–108
Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol 13:790–801
Globocan (2012) Estimated cancer incidence, mortality and prevalence worldwide in 2012. Online analysis > prediction. International Agency for the Research on Cancer, Lyon
Acknowledgments
Support was provided by Washington University School of Medicine (GSAS/CGFP Fund 94028C) (WAW), and by the Cancer Center Support Grant Number P30CA072720 from the National Cancer Institute (through a New Investigator Award awarded to AAML). We acknowledge the assistance of Stephan Samuell, Central Statistical Office in Trinidad & Tobago. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the affiliating organizations.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors have no conflicts of interest to disclose.
Rights and permissions
About this article
Cite this article
Llanos, A.A.M., Warner, W.A., Luciani, S. et al. Gynecologic cancer mortality in Trinidad and Tobago and comparisons of mortality-to-incidence rate ratios across global regions. Cancer Causes Control 28, 1251–1263 (2017). https://doi.org/10.1007/s10552-017-0961-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-017-0961-4